TD Cowen analyst Joseph Thome has maintained their bullish stance on TRDA stock, giving a Buy rating on October 28.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Thome has given his Buy rating due to a combination of factors including the promising advancements in Entrada Therapeutics Inc’s Duchenne Muscular Dystrophy (DMD) franchise. The company has successfully completed enrollment for the first cohort in its Phase I/IIb trial for exon 44 amenable mutations and is expected to release data by the second quarter of 2026. This progress is indicative of a robust pipeline, with additional candidates targeting exon 45, 50, and 51 mutations expected to enter or approach clinical trials in the same year.
Furthermore, the regulatory landscape for DMD therapies remains favorable, as evidenced by recent developments with other companies’ programs. Entrada’s management is optimistic about their EEV platform’s potential to deliver best-in-class dystrophin production, which could set their therapies apart in terms of efficacy and safety. These strategic advancements and the company’s strong positioning in the evolving DMD market underpin Thome’s Buy rating for TRDA.
Thome covers the Healthcare sector, focusing on stocks such as United Therapeutics, PTC Therapeutics, and AnaptysBio. According to TipRanks, Thome has an average return of 20.6% and a 56.00% success rate on recommended stocks.
In another report released on October 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.